Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma Dividend Announcement
• Lyell Immunopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Lyell Immunopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
Lyell Immunopharma Dividend History
Lyell Immunopharma Dividend Yield
Lyell Immunopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Lyell Immunopharma stock? Use our calculator to estimate your expected dividend yield:
Lyell Immunopharma Financial Ratios
Lyell Immunopharma Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Lyell Immunopharma stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.